Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments

Xia Xiaoping

doi:10.13406/j.cnki.cyxb.002820

您当前的位置：

首页 >

文章列表页 >

Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments

更新时间：2024-01-09

- Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments
- Journal of Chongqing Medical University Vol. 46, Issue 6, Pages: 691-695(2021)
- 作者机构：
  
  中国科学技术大学附属第一医院西区/安徽省肿瘤医院妇瘤科,合肥,230032
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002820
  CLC： R739.9
- Published：2021，
扫描看全文
Xia Xiaoping. Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments. [J]. Journal of Chongqing Medical University 46(6):691-695(2021)
DOI：

Xia Xiaoping. Analysis of the efficacy and life quality of cervical cancer patients with intermediate risk after operation by different adjuvant treatments. [J]. Journal of Chongqing Medical University 46(6):691-695(2021) DOI： 10.13406/j.cnki.cyxb.002820.

摘要

目的：比较单纯化疗或同步放化疗辅助治疗宫颈癌（IB1~IIA2）术后存在中危因素患者的临床疗效及远期毒副反应，并进行生活质量评估，探讨该类患者术后采用单纯化疗的可行性。方法：回顾性分析2016年2月至2018年4月就诊于安徽省肿瘤医院妇瘤科术后宫颈癌存在中危因素的患者。入组患者均行标准宫颈癌手术，术后根据辅助治疗途径分为化疗组和同步放化疗组，通过治疗的有效性、远期毒副反应及生存质量等指标探讨2种辅助治疗方式的临床疗效及安全性。结果： 2组间的复发率（χ2=0.288，P=0.591）和病死率（χ2=0.238，P=0.625）比较差异均无统计学意义；化疗组的3年无进展生存率（87.70%）和3年总生存率（97.60%）高于同步放化疗组（分别为81.40%和89.70%），差异均无统计学意义（χ2=0.787，P=0.375；χ2=1.441，P=0.230）；化疗组（16.70%）淋巴水肿的发生率低于放化疗组（37.21%），差异有统计学意义（χ2=4.543，P=0.033）；化疗组的生活质量得分（88.28±5.84）高于放化疗组（78.60±8.32），差异有统计学意义（t=6.020，P<0.001）。结论：单纯化疗辅助治疗IB1~IIA2期宫颈癌根治术后具有中危因素的患者，也能获得较好的临床效果，并且毒副反应略轻于放化疗组，可以作为一种备选的辅助治疗方式供临床选择。

Abstract

Objective: To compare the effectiveness and long-term side effects of adjuvant therapy for patients with cervical cancer (IB1-IIA2) with intermediate-risk factors in pathology after chemotherapy alone or concurrent radiotherapy and chemotherapy

and to evaluate the quality of life and explore the feasibility of using chemotherapy alone for cervical cancer patients. Methods: Cervical cancer patients with intermediate risk factors after surgery in the Department of Gynecological Oncology

The First Affiliated Hospital of USTC West District/Anhui Provincial Cancer Hospital from February 2016 to April 2018 were retrospectively analyzed in this study. All patients underwent standard cervical cancer surgery

and were divided into chemotherapy group and concurrent radiotherapy and chemotherapy group according to the adjuvant treatment methods after surgery. The clinical efficacy and safety of the two adjuvant treatments were discussed through the indicators of treatment effectiveness

long-term toxic side effects and quality of life of the two groups. Results: There was no significant difference in cervical cancer recurrence (χ2=0.288

P=0.591) and mortality (χ2=0.238

P=0.625) between the two groups. The 3-year progression-free survival (87.70%) and 3-year overall survival (97.60%) of the radiotherapy and chemotherapy group were lower than those of chemotherapy group (81.40% and 89.70%

respectively)

without significant differences (χ2=0.787

P=0.375; χ2=1.441

P=0.230). The incidence of lymphedema in the chemotherapy group (16.70%) was lower than that of the radiotherapy and chemotherapy group (37.21%)

with significant differences (χ2=4.543

P=0.033). The quality of life scores of the chemotherapy group (88.28±5.84) were higher than those of the radiotherapy and chemotherapy group (78.60±8.32)

with significant differences (t=6.020

P<0.001). Conclusion: Chemotherapy alone for adjuvant treatment of patients with intermediate risk factors after radical resection of IB1-IIA2 cer-vical cancer can also achieve better clinical results

and the side effects are slightly lighter than those in the radiotherapy and chemotherapy group

which can be used as an alternative adjuvant treatment.

关键词

宫颈癌中危因素化疗放化疗

Keywords

cervical cancerintermediate risk factorschemotherapyradiotherapy and chemotherapy

references

Views

110

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Therapeutic options and prognostic analysis for patients with FIGO 2018 stageⅠA2-ⅡA1 cervical cancer

Progress of MRI in predicting the recurrence and metastasis of cervical cancer after radiotherapy and chemotherapy

Cervical cancer screening system TruScreen with graph neural network-based classification versus HPV DNA quantification in high-risk HPV-positive patients

Research progress on artificial intelligence in screening and precise diagnosis and treatment of cervical cancer

Related Author

Xia Xiaoping

Shen Wei

Ni Jin

Xia Bairong

Zhang Na

Cao Yuan

Hu Yanli

Zhou Leming

Related Institution

Second Department of Radiotherapy,The First Affiliated Hospital of USTC West District/Anhui Provincial Cancer Hospital

Gynecological Cancer Center, Chongqing University Cancer Hospital

Department of Gynecological Oncology, The 4th Hospital of Hebei Medical University

Science and Education Department，Yubei District People’s Hospital of Chongqing

Department of Clinical Laboratory， Qianjiang Hospital，Chongqing University

⁰